Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

 Developed to address EGFR inhibitor-induced skin toxicities in cancer patients

NEW YORK, June 23, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they will host a virtual Key Opinion Leader (KOL) event on Tuesday, June 24, 2025, at 3:30PM EST. Access/join the event through the following link: https://zoom.us/j/91353016981.

Read more at prnewswire.com